Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Johnson & Johnson Innovation, LLC
-- Deals span new approaches for cancer, diabetes, autoimmune disease and Alzheimer's, exciting technologies such as 3-D printing for trauma use, sedation monitoring, cardiac remodeling, probiotics for skin infections --
NEW BRUNSWICK, N.J., June 19, 2014 /PRNewswire/ -- Johnson & Johnson Innovation, LLC today announced 12 new alliances with life science companies and research institutions around the globe to explore early-stage innovation in a broad range of therapeutic areas and across pharmaceuticals, medical device and diagnostics and consumer healthcare.
"The future of healthcare will be defined by companies, academic institutions and governments that collaborate to leverage existing strengths, while at the same time think outside current paradigms and experiment with new ways of innovating," said Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson and Worldwide Chairman, Pharmaceuticals. "By being where these new frontiers in science and technology are being forged, our goal is to translate these insights into promising treatments for the future."
Launched more than a year ago, the Johnson & Johnson Innovation centers are working globally with life science researchers and entrepreneurs to identify exciting early-stage technologies and translate them into solutions for patients.
The early-stage collaborations announced today represent recent research and development alliances facilitated by the Boston, California and London innovation centers and include exciting technologies like 3-D printing for orthopaedic trauma, creating new brown fat for metabolic diseases and advancing novel science in areas of significant unmet medical need such as lymphoma, rheumatoid arthritis, prostate cancer, dementia, Alzheimer's, diabetes and insomnia.
"The broad variety of the collaborations we are announcing today, and the unique ways in which we are working with our collaborators, illustrates our strong commitment to being flexible and creative in our deal making in order to maximize the potential of each individual technology," added Dr. Stoffels. "Our goal is to enrich the life science ecosystem on a global scale by redefining the R&D paradigm."
The collaborations include:
Promising New Ways to Treat Cancer
Patient-Specific 3D Printing for Orthopedic Needs
Advancing Progress on Alzheimer's Disease and Neuroscience
Seeking Novel Approaches to Treat Diabetes and Cardiovascular Disease
Targeting Autoimmune Disease
New Strategies for Skin, Oral and Respiratory Conditions
Johnson & Johnson Innovation launched the innovation centers last year, establishing four regional hubs to identify scientific opportunities with the potential to advance the development of new healthcare solutions. Through the innovation centers, external innovators have access to a broad range of resources within Johnson & Johnson, including funding, R&D expertise and incubation at one of the company's four Janssen Labs facilities. Today, there are fully operational offices in Boston, London and California, and a fourth location in Shanghai now houses a small, growing scientific team and will officially open this year to develop collaborations across the Asia Pacific region.
About Johnson & Johnson Innovation
Johnson & Johnson Innovation, LLC focuses on accelerating early-stage innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson's global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and diagnostics and consumer companies of Johnson & Johnson. Johnson & Johnson Innovation includes local deal-making capabilities with the flexibility to adapt deal structures to match early-stage opportunities and establish novel collaborations that speed development of innovations to solve unmet needs in patients.
Johnson & Johnson Innovation facilitates early stage collaborations across the Johnson & Johnson Family of Companies. For more information please visit: www.jnjinnovation.com
(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson Innovation, LLC and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; changes to governmental laws and regulations and domestic and foreign health care reforms; general industry conditions including trends toward health care cost containment; and increased scrutiny of the health care industry by government agencies. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 29, 2013, including in Exhibit 99 thereto, and our subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Neither Johnson & Johnson Innovation LLC nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.)
©2012 PR Newswire. All Rights Reserved.